These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 30070426)

  • 21. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA.
    Wilner SE; Levy M
    Methods Mol Biol; 2016; 1380():211-24. PubMed ID: 26552829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aptamer-targeted RNAi for HIV-1 therapy.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
    Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
    Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A universal protein tag for delivery of SiRNA-aptamer chimeras.
    Liu HY; Gao X
    Sci Rep; 2013 Nov; 3():3129. PubMed ID: 24196104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy.
    Kruspe S; Giangrande PH
    Methods Mol Biol; 2017; 1632():175-186. PubMed ID: 28730439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aptamer-siRNA chimeras for HIV.
    Takahashi M; Burnett JC; Rossi JJ
    Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic potential of cell-internalizing aptamers.
    Zhou J; Rossi JJ
    Curr Top Med Chem; 2009; 9(12):1144-57. PubMed ID: 19860714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenging cancer targets for aptamer delivery.
    de Franciscis V
    Biochimie; 2018 Feb; 145():45-52. PubMed ID: 28962871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery.
    Yoo H; Jung H; Kim SA; Mok H
    Chem Commun (Camb); 2014 Jun; 50(51):6765-7. PubMed ID: 24830507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.
    Vandghanooni S; Eskandani M; Barar J; Omidi Y
    J Mol Med (Berl); 2018 Sep; 96(9):885-902. PubMed ID: 30056527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
    Gilboa E; Berezhnoy A; Schrand B
    Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA.
    Zhu Q; Shibata T; Kabashima T; Kai M
    Eur J Med Chem; 2012 Oct; 56():396-9. PubMed ID: 22907035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges.
    He F; Wen N; Xiao D; Yan J; Xiong H; Cai S; Liu Z; Liu Y
    Curr Med Chem; 2020; 27(13):2189-2219. PubMed ID: 30295183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.
    Kim M; Kim DM; Kim KS; Jung W; Kim DE
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.
    de Almeida CEB; Alves LN; Rocha HF; Cabral-Neto JB; Missailidis S
    Int J Pharm; 2017 Jun; 525(2):334-342. PubMed ID: 28373101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.